How Much Further Can AstraZeneca plc, Unilever plc And Rolls-Royce Holding PLC Fall?

Is it time to load up on AstraZeneca plc (LON: AZN), Unilever plc (LON: ULVR) and Rolls-Royce Holding PLC (LON: RR)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

What do you do when quality shares fall in price without the company itself doing anything wrong? If you’re a long-term investor, you buy, of course!

Look at drugs giant AstraZeneca (LSE: AZN). It was out of favour for a while when both it and rival GlaxoSmithKline were hit by the loss of patents on key products and increasing generic competition, but investors took a quick shine to new boss Pascal Soriot and his back-to-basics turnaround plan and the share price started picking up again.

But with the latest China-led stock market crunch, we’ve seen AstraZeneca shares turn tail once more — the price is down more than 8% in just the past five days, to 3,964p, and it’s fallen 18% since 2015’s high point in April. The price fall brings AstraZeneca’s forward P/E based on 2016 forecasts down to 15, which looks cheap around the expected bottom in the earnings cycle, especially with a 4.4% dividend yield forecast.

If you thought AstraZeneca was worth buying a week ago, then surely it’s a better bargain now, isn’t it?

Time to clean up?

Unilever (LSE: ULVR) is another stalwart whose price has dipped, with a loss of 13% since 6 August, to 2,572p as I write. To be fair, Unilever does sell a fair bit of its soapy things in the Asian region, but slowing Chinese growth is unlikely to cause any real upset. With EPS predicted to grow at 10% this year, Unilever shares are now on a forward P/E of around 20 — though forecasts could be downgraded a little.

Unilever always looks too highly priced to me and I fear there could be a little more downside yet, but solid defensive stocks are often afforded such premiums by institutional investors. So if you’re looking to pick up such shares in the dips, now could be your chance.

One attraction of Unilever is its dividends, and the share price fall has upped the forecast yields to 3.2% and 3.4% for this year and next. It’s not one of the biggest yields on the market, but it should be well covered by earnings and is generally considered very reliable.

Aerospace bargain?

Rolls-Royce (LSE: RR) shares have been falling after the company that has traditionally just kept on growing its earnings shocked the market with a string of profit warnings. From a peak of nearly £13 in January 2014, the shares have lost a whopping 44% to trade at 721p as I write – a little up from the 685.5p low hit on Monday in the immediate wake of the China crash.

There’s still a couple of years of earnings falls forecast for Rolls-Royce, but with a 2016 P/E of 16 and with dividends set to yield a decently-covered 3% or so, this looks like another that could be undervalued at the bottom of a cycle.

The fundamental nature of these three is unaffected by this week’s market fallout, and they’re just the same companies they were last week — but there will still be people selling out in fear of further irrational panic.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK owns and has recommended Unilever, and has recommended Glaxo. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s how I’d aim for a ton of passive income from £20k in an ISA

To get the best passive income from an ISA, I think we need to balance risk with the potential rewards.…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

2 FTSE 100 stocks I’d buy as the blue-chip index hits record highs

This Fool takes a look at a pair of quality FTSE 100 stocks that appear well-positioned for future gains, despite…

Read more »

Satellite on planet background
Small-Cap Shares

Here’s why AIM stock Filtronic is up 44% today

The share price of AIM stock Filtronic has surged on the back of some big news in relation to its…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

At a record high, there can still be bargain FTSE 100 shares to buy!

The FTSE 100 closed at a new all-time high this week. Our writer explains why there might still be bargain…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

After profits plunge 28%, should investors consider buying Lloyds shares?

Lloyds has seen its shares wobble following the release of its latest results. But is this a chance for investors…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

Something’s changed in a good way for Reckitt in Q1, and the share price may be about to take off

With the Reckitt share price near 4,475p, is this a no-brainer stock? This long-time Fool takes a closer look at…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

This new boost in assets might just get the abrdn share price moving again

The abrdn share price has lost half its value in the past five years. But with investor confidence returning, are…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

As revenues rise 8%, is the Croda International share price set to bounce back?

The latest update from Croda International indicates that sales are starting to recover from the end of 2023, so is…

Read more »